Accuray Inc.

Snapshot

Accuray is a radiation-therapy equipment maker whose revenue shrank 12% to $401.9M in fiscal 2026 and posted a $49.2M net loss.

What's Happening Right Now

• Tue 6th Oct '26 · Financing deal: On Oct 6, 2026, stockholders approved a TCW-led rescue package: a $40M debt-for-preferred swap, a $15M equity investment, covenant relief through 2027, and a reverse split of 1-for-15 to 1-for-40.
• Fri 11th Sep '26 · Dilution: A September 2026 prospectus registered resale of 6.8M warrant shares tied to an $18.25M loan draw, with total lender warrants covering roughly 44% of shares outstanding, many deeply in the money at a $0.01 strike.
• Fri 11th Sep '26 · Partnership: On Sept 11, 2026, Accuray and RaySearch signed a collaboration integrating RayStation software with Accuray's platforms to advance its online adaptive radiation therapy capabilities.
• Fri 11th Sep '26 · Registration: Registered 6.83M shares for sale on Form S-3.
• Thu 10th Sep '26 · Earnings: Fiscal 2026 revenue fell 12% to $401.9M with a $49.2M net loss; Q4 orders dropped sharply and backlog fell 27%, and management withdrew fiscal 2027 guidance.
• Wed 9th Sep '26 · Listing risk: Nasdaq moved Accuray down to the Capital Market tier effective Aug 6, 2026, giving the company until Feb 1, 2027 to get its share price back above $1 or face delisting.
• Wed 29th Jul '26 · Warrants: Issued warrants over 15.25M shares.
• Mon 18th May '26 · Offering: Closed an offering. Proceeds are not disclosed in the filings reviewed, with warrants over 6.83M shares.